CorMedix (CRMD)

• Market cap: $758M
• 1 day: 2.63%
• 5 days: 11.12%
• 1 month: 48.34%
• 3 months: 11.52%
• 6 months: 163.50%
• Year to date: 51.95%
• 1 year: 280.79%
• 5 years: 76.41%
• 10 years: 9.08%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

106% more capital invested

Capital invested by funds: $75.6M [Q2] → $156M (+$80.3M) [Q3]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

34% more call options, than puts

Call options by funds: $5.85M | Put options by funds: $4.35M

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

3% more funds holding

Funds holding: 99 [Q2] → 102 (+3) [Q3]

2.81% more ownership

Funds ownership: 31.76% [Q2] → 34.58% (+2.81%) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 4% downside
• Avg. target: $15.50 24% upside
• High target: $18 44% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target	20% upside $15	Buy Initiated	13 Jan 2025
RBC Capital Gregory Renza 30% 1-year accuracy 26 / 86 met price target	4% downside $12	Outperform Maintained	19 Dec 2024
Needham Serge Belanger 35% 1-year accuracy 46 / 130 met price target	44% upside $18	Buy Maintained	31 Oct 2024
Truist Securities Joon Lee 50% 1-year accuracy 21 / 42 met price target	36% upside $17	Buy Maintained	22 Oct 2024